Epirubicin, cyclophosphamide and pyrotinib followed by docetaxel, trastuzumab and pyrotinib as neoadjuvant therapy for stage II-III HER2-positive breast cancer: a single-arm, multicenter phase 2 trial

被引：0
|
作者：
Shi, Qiyun
Qi, Xiaowei
Tang, Peng
Fan, Linjun
Chen, Li
Wang, Shushu
Zhang, Guozhi
Wang, Mengyuan
Che, Hongying
Lv, Pengwei
Chen, Dejie
Hu, Jinhui
Li, Qiuyun
Zhang, Yanwu
Yu, Qiao
Yang, Kunxian
Zhong, Yuan
Chen, Chuang
Zhou, Zemin
Qian, Liyuan
Zhang, Jingwei
Ma, Mingde
Sun, Yi
Liu, Jiangbo
Zhang, Yi
Jiang, Jun
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT2-22-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-22-01
引用
收藏
页数：3
相关论文
共 50 条
  • [1] A multicenter single-arm trial of neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer
    Shi, Qiyun
    Qi, Xiaowei
    Tang, Peng
    Fan, Linjun
    Chen, Li
    Wang, Shushu
    Liang, Yan
    Hu, Ying
    Wang, Minghao
    Ren, Lin
    Zhang, Guozhi
    Tan, Xuanni
    Yuan, Long
    Du, Junze
    Wu, Xiujuan
    Wang, Mengyuan
    Che, Hongying
    Lv, Pengwei
    Chen, Dejie
    Hu, Jinhui
    Li, Qiuyun
    Zhang, Yanwu
    Yang, Kunxian
    Zhong, Yuan
    Chen, Chuang
    Zhou, Zemin
    Qian, Liyuan
    Zhang, Jingwei
    Ma, Mingde
    Sun, Yi
    Zhang, Yi
    Jiang, Jun
    MEDCOMM, 2023, 4 (06):
  • [2] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Min Yan
    Limin Niu
    Huimin Lv
    Mengwei Zhang
    Jing Wang
    Zhenzhen Liu
    Xiuchun Chen
    Zhenduo Lu
    Chongjian Zhang
    Huiai Zeng
    Shengnan Zhao
    Yajing Feng
    Huihui Sun
    Huajun Li
    Nature Communications, 14
  • [3] Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial
    Yan, Min
    Niu, Limin
    Lv, Huimin
    Zhang, Mengwei
    Wang, Jing
    Liu, Zhenzhen
    Chen, Xiuchun
    Lu, Zhenduo
    Zhang, Chongjian
    Zeng, Huiai
    Zhao, Shengnan
    Feng, Yajing
    Sun, Huihui
    Li, Huajun
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [4] Neoadjuvant pyrotinib plus trastuzumab and chemotherapy for stage I-III HER2-positive breast cancer: Results of a single-arm pilot clinical trial
    Jiang, Jun
    CANCER RESEARCH, 2021, 81 (04)
  • [5] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
    Cao, Jun
    Teng, Yuee
    Li, Huiping
    Zhang, Lili
    Ouyang, Quchang
    Xie, Weimin
    Pan, Yueyin
    Song, Zhenchuan
    Ling, Xiaoling
    Wu, Xiaohong
    Xu, Jingwei
    Li, Li
    Ren, Liping
    Wang, Hong
    Zhou, Dongxian
    Luo, Jing
    Hu, Xichun
    BMC MEDICINE, 2023, 21 (01)
  • [6] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
    Jun Cao
    Yuee Teng
    Huiping Li
    Lili Zhang
    Quchang Ouyang
    Weimin Xie
    Yueyin Pan
    Zhenchuan Song
    Xiaoling Ling
    Xiaohong Wu
    Jingwei Xu
    Li Li
    Liping Ren
    Hong Wang
    Dongxian Zhou
    Jing Luo
    Xichun Hu
    BMC Medicine, 21
  • [7] Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase II trial
    Wang, X.
    Huang, J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S646 - S647
  • [8] Pyrotinib in combination with docetaxel as first-line treatment for HER2-positive metastatic breast cancer (PANDORA): A single-arm, multicenter phase 2 trial
    Wang, Xiaojia
    Huang, Jian
    Zheng, Yabing
    Shao, Xiying
    Cao, Wenming
    Chen, Zhanhong
    Shi, Yanxia
    Cai, Li
    Chen, Wenyan
    Guo, Zhen
    Liu, Jian
    Shen, Peng
    Chen, Yiding
    Wang, Xian
    Li, Huiping
    Li, Man
    CANCER RESEARCH, 2022, 82 (04)
  • [9] Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: A single-group, multicenter, phase II study
    Liu, Z.
    Zhu, J.
    Wang, C.
    Sun, X.
    Lu, Z.
    Chen, X.
    Wang, H.
    Mao, S.
    Zhou, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S331 - S331
  • [10] Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial
    Zhao, Jianli
    Yu, Yunfang
    Ren, Wei
    Ding, Linxiaoxiao
    Chen, Yongjian
    Yuan, Peng
    Yue, Jian
    Yang, Yaping
    Zou, Guorong
    Chen, Tao
    Chai, Jie
    Zhang, Li
    Wu, Wenjing
    Zeng, Yinduo
    Gui, Xiujuan
    Cai, Yangyang
    Luo, Simin
    Yuan, Zhongyu
    Zhang, Kang
    Yao, Herui
    Wang, Ying
    MEDCOMM, 2025, 6 (01):
12345